公开(公告)号：US11882846B2

公开(公告)日：2024-01-30

申请号：US17535829

申请日：2021-11-26

申请人： National Chung Hsing University

发明人： Chuan-Mu Chen ,  Hsiao-Ling Chen

IPC分类号： A23C9/127 ,  A61P25/24 ,  A23C9/13

CPC分类号： A23C9/127 ,  A23C9/1307 ,  A61P25/24

摘要： The invention discloses that a kefir peptide with an amino acid sequence of SEQ ID No: 2 or a fermentation product comprising the kefir peptide has an antidepressant activity, which means that by administering an effective amount of the kefir peptide or a composition comprising an effective amount of the kefir peptide to an individual with depressive behaviors is capable of effectively improving or alleviating the individual's depressive behaviors. Since the kefir peptide disclosed in the invention is not a chemical compound, the kefir peptide will not have side effects on the human body even taking it on a long-term basis.

公开(公告)号：US11771102B2

公开(公告)日：2023-10-03

申请号：US17223456

申请日：2021-04-06

申请人： H.J. Heinz Company Brands LLC

发明人： Andrea Budelli ,  Francesca Romana Fasano ,  Miryam Terzano ,  Lorenzo Bramati

IPC分类号： A23C9/123 ,  A23L7/104 ,  A23L7/10 ,  A23L19/00 ,  A23L33/135 ,  A61K35/747 ,  A23C9/127 ,  A23L33/00 ,  A61K35/00

CPC分类号： A23C9/1234 ,  A23C9/127 ,  A23L7/10 ,  A23L7/104 ,  A23L19/00 ,  A23L33/135 ,  A23L33/40 ,  A61K35/747 ,  A23V2002/00 ,  A23Y2220/63 ,  A61K2035/115

摘要： The present invention features compositions and methods for modulation of the mucosal immune system. The compositions include foods fermented by the probiotic organism, Lactobacillus paracasei CBA L74 (International Depository Accession Number LMG P-24778). Alternatively the compositions can include L. paracasei CBA L74 and a physiologically acceptable carrier. In some embodiments, the L. paracasei CBA L74 can be non-replicating. The compositions can be administered to a subject having or at risk for gastrointestinal disorders related to immaturity of the immune system, infection or disease.

公开(公告)号：US09623056B2

公开(公告)日：2017-04-18

申请号：US15258811

申请日：2016-09-07

申请人： Crestovo LLC

发明人： Thomas Julius Borody

IPC分类号： A61K39/00 ,  A61K39/38 ,  A61K39/02 ,  A61K39/08 ,  A61K39/108 ,  A61K35/742 ,  A61K35/74 ,  A61K38/48 ,  A61K35/741 ,  A61K35/744 ,  A61K35/747 ,  A61K36/062 ,  A61K45/06 ,  A61K38/14 ,  A61K31/341 ,  A61K31/41 ,  A61K31/495 ,  A61K31/7034 ,  A23L2/52 ,  A61K35/745 ,  A61K35/38 ,  A61K35/24 ,  A61K9/00 ,  A23C9/123 ,  A61K9/48 ,  A23C9/13 ,  A23L33/135 ,  A23C9/127 ,  A61K9/19 ,  A61K35/37 ,  A61K31/545 ,  A61K35/76 ,  A61K31/43 ,  A61K38/00 ,  A61K31/7048 ,  A61K9/50 ,  A61K39/39 ,  A61K51/12 ,  A61K35/00

CPC分类号： A61K35/742 ,  A23C9/123 ,  A23C9/127 ,  A23C9/13 ,  A23L2/52 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K9/48 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/41 ,  A61K31/43 ,  A61K31/495 ,  A61K31/545 ,  A61K31/7034 ,  A61K31/7048 ,  A61K35/24 ,  A61K35/37 ,  A61K35/38 ,  A61K35/74 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K36/062 ,  A61K38/00 ,  A61K38/14 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61K51/1217 ,  A61K2035/115 ,  C12N2795/00032 ,  Y02A50/401 ,  Y02A50/469 ,  Y02A50/473 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

公开(公告)号：US20160375067A1

公开(公告)日：2016-12-29

申请号：US15260879

申请日：2016-09-09

申请人： Crestovo LLC

发明人： Thomas Julius BORODY

IPC分类号： A61K35/741 ,  A61K9/48 ,  A61K38/14 ,  A61K35/742

CPC分类号： A61K35/742 ,  A23C9/123 ,  A23C9/127 ,  A23C9/13 ,  A23L2/52 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K9/48 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/41 ,  A61K31/43 ,  A61K31/495 ,  A61K31/545 ,  A61K31/7034 ,  A61K31/7048 ,  A61K35/24 ,  A61K35/37 ,  A61K35/38 ,  A61K35/74 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K36/062 ,  A61K38/00 ,  A61K38/14 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61K51/1217 ,  A61K2035/115 ,  C12N2795/00032 ,  Y02A50/401 ,  Y02A50/469 ,  Y02A50/473 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

公开(公告)号：US20160279179A1

公开(公告)日：2016-09-29

申请号：US15178539

申请日：2016-06-09

申请人： Crestovo LLC

发明人： Thomas Julius BORODY

IPC分类号： A61K35/742 ,  A61K35/741 ,  A61K9/50 ,  A61K9/00

CPC分类号： A61K35/742 ,  A23C9/123 ,  A23C9/127 ,  A23C9/13 ,  A23L2/52 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K9/48 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/41 ,  A61K31/43 ,  A61K31/495 ,  A61K31/545 ,  A61K31/7034 ,  A61K31/7048 ,  A61K35/24 ,  A61K35/37 ,  A61K35/38 ,  A61K35/74 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K36/062 ,  A61K38/00 ,  A61K38/14 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61K51/1217 ,  A61K2035/115 ,  C12N2795/00032 ,  Y02A50/401 ,  Y02A50/469 ,  Y02A50/473 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

公开(公告)号：US09408872B2

公开(公告)日：2016-08-09

申请号：US14793642

申请日：2015-07-07

申请人： Crestovo LLC

发明人： Thomas Julius Borody

IPC分类号： A61K45/00 ,  A01N63/00 ,  A61M36/14 ,  A61K9/16 ,  A61K9/50 ,  A61K35/24 ,  A61K35/74 ,  A61K38/48 ,  A23L1/30 ,  A61K35/741 ,  A61K35/742 ,  A61K35/744 ,  A61K35/747 ,  A61K36/062 ,  A61K45/06 ,  A61K38/14 ,  A61K31/341 ,  A61K31/41 ,  A61K31/495 ,  A61K31/7034 ,  A23L2/52 ,  A61K35/745 ,  A61K35/38 ,  A61K31/545 ,  A61K39/00 ,  A61K35/76 ,  A61K31/43 ,  A61K38/00 ,  A61K31/7048 ,  A61K39/39 ,  A61K51/12 ,  A61K35/00

CPC分类号： A61K35/742 ,  A23C9/123 ,  A23C9/127 ,  A23C9/13 ,  A23L2/52 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K9/48 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/41 ,  A61K31/43 ,  A61K31/495 ,  A61K31/545 ,  A61K31/7034 ,  A61K31/7048 ,  A61K35/24 ,  A61K35/37 ,  A61K35/38 ,  A61K35/74 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K36/062 ,  A61K38/00 ,  A61K38/14 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61K51/1217 ,  A61K2035/115 ,  C12N2795/00032 ,  Y02A50/401 ,  Y02A50/469 ,  Y02A50/473 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides , Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

摘要翻译： 本发明涉及适用于治疗与在哺乳动物宿主的胃肠道中存在异常或异常分布的微生物群落有关的慢性疾病的药物组合物，该组合物包含活的非致病性或减毒的病原性梭菌。 所述组合物还包含选自拟杆菌属，真细菌属，细菌杆菌属，丙酸杆菌属，乳杆菌属，厌氧球菌，球菌属，大肠杆菌，Gemmiger，Desulfomonas，消化链球菌和真菌的一种或多种另外的活的非致病或减毒病原微生物。 本发明还提供适用于治疗相同慢性疾病的药物组合物，其包含活的非致病性或减毒致病性大肠杆菌，至少一种活的非致病性或减毒致病性拟杆菌菌株和至少一种存活的非致病性菌株 或减毒病原微生物。

公开(公告)号：US20160165910A1

公开(公告)日：2016-06-16

申请号：US14905125

申请日：2014-07-16

申请人： DUPONT NUTRITION BIOSCIENCES APS

发明人： Philippe Horvath ,  Christophe Fremaux ,  Pascal Fourcassie

IPC分类号： A23C9/123 ,  C12R1/46

CPC分类号： A23C9/1238 ,  A23C9/127 ,  A23C19/032 ,  A23C21/02 ,  A23L33/135 ,  A23V2002/00 ,  A23Y2240/75 ,  C12N1/20 ,  C12R1/46

摘要： The present invention relates to Streptococcus thermophilus strains, usable as starter cultures, able to provide both satisfactory rheological and organoleptic properties, and satisfactory shelf life to the media into which they are incorporated. In particular, these strains are al so bacteriophage-resistant, thereby minimizing bacteriophage infection. The invention also provides a composition comprising one of these Streptococcus thermophilus strains, and feed or food products obtained with these strains.

摘要翻译： 本发明涉及可用作起始培养物的嗜热链球菌菌株，其能够提供令人满意的流变学和感官特性，以及其引入其中的培养基的令人满意的保存期限。 特别地，这些菌株具有抗噬菌体抗性，从而使噬菌体感染最小化。 本发明还提供了包含这些嗜热链球菌菌株之一的组合物，以及用这些菌株获得的饲料或食品。

公开(公告)号：US20160151433A1

公开(公告)日：2016-06-02

申请号：US15017380

申请日：2016-02-05

申请人： Thomas Julius BORODY

发明人： Thomas Julius BORODY

IPC分类号： A61K35/742 ,  A61K9/00 ,  A61K35/744 ,  A23C9/123 ,  A61K9/50 ,  A61K31/341 ,  A61K38/14 ,  A61K35/741 ,  A61K9/48

CPC分类号： A61K35/742 ,  A23C9/123 ,  A23C9/127 ,  A23C9/13 ,  A23L2/52 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K9/48 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/41 ,  A61K31/43 ,  A61K31/495 ,  A61K31/545 ,  A61K31/7034 ,  A61K31/7048 ,  A61K35/24 ,  A61K35/37 ,  A61K35/38 ,  A61K35/74 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K36/062 ,  A61K38/00 ,  A61K38/14 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61K51/1217 ,  A61K2035/115 ,  C12N2795/00032 ,  Y02A50/401 ,  Y02A50/469 ,  Y02A50/473 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

公开(公告)号：US20160151429A1

公开(公告)日：2016-06-02

申请号：US15017364

申请日：2016-02-05

申请人： Thomas Julius BORODY

发明人： Thomas Julius BORODY

IPC分类号： A61K35/741 ,  A61K35/747 ,  A61K35/745 ,  A61K35/742 ,  A61K9/00 ,  A61K45/06

CPC分类号： A61K35/742 ,  A23C9/123 ,  A23C9/127 ,  A23C9/13 ,  A23L2/52 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K9/48 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/41 ,  A61K31/43 ,  A61K31/495 ,  A61K31/545 ,  A61K31/7034 ,  A61K31/7048 ,  A61K35/24 ,  A61K35/37 ,  A61K35/38 ,  A61K35/74 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K36/062 ,  A61K38/00 ,  A61K38/14 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61K51/1217 ,  A61K2035/115 ,  C12N2795/00032 ,  Y02A50/401 ,  Y02A50/469 ,  Y02A50/473 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

公开(公告)号：US20150306156A1

公开(公告)日：2015-10-29

申请号：US14793642

申请日：2015-07-07

申请人： Thomas Julius BORODY

发明人： Thomas Julius BORODY

IPC分类号： A61K35/742 ,  A61K35/745 ,  A61K35/741 ,  A61K35/747 ,  A61K45/06 ,  A61K38/14

CPC分类号： A61K35/742 ,  A23C9/123 ,  A23C9/127 ,  A23C9/13 ,  A23L2/52 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0031 ,  A61K9/0053 ,  A61K9/19 ,  A61K9/48 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/41 ,  A61K31/43 ,  A61K31/495 ,  A61K31/545 ,  A61K31/7034 ,  A61K31/7048 ,  A61K35/24 ,  A61K35/37 ,  A61K35/38 ,  A61K35/74 ,  A61K35/741 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K36/062 ,  A61K38/00 ,  A61K38/14 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61K51/1217 ,  A61K2035/115 ,  C12N2795/00032 ,  Y02A50/401 ,  Y02A50/469 ,  Y02A50/473 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.